The FDA is provided guidance to assist sponsors in developing vaccine to protect against global infectious diseases. The guidance focuses on development of licence of vaccines for infectious diseases or conditions endemic in areas outside the United States. It aims to clarify regulatory status and guidance already published for development of these products.
Full guidance given below
Posted in clinical, pre-clinical
Tagged FDA, global, guidance, infectious disease, vaccine development
This Excel file contains change history and the breakdown of our questions submitted on eCTD structure and specifications.
This file should be viewed in Excel and can be downloaded from the FDA website
Posted in regulatory
Tagged eCTD, electronic common technical dossier, FDA, M2, specification
This guidance is being developed for applicants of new drug application is an abbreviated drug applications in order to give them an insight into the agency’s current thinking on the classification of co-crystal solid-state forms. It also provides information about the data that should be submitted to support the appropriate classification and the regulatory implications of classification.
Full guidance given below
This guidance is intended for blood establishments the manufacturer whole blood and blood components including source plasma and source leucocytes. It provides guidance for the re-qualification method or process for the re-entry of deferred donors who test repeatedly reactive for hepatitis B surface antigens, confirmed positive by neutralisation, following a recent vaccination for hepatitis B infection, and who are not infected by hepatitis B virus.
Full guidance given below
Posted in biotechnology, market access
Tagged blood donor, FDA, hepatitis B, screening, vaccination
The FDA is provided this guidance in order to make recommendations to industry for describing the nonclinical late radiation toxicity studies to determine potential late radiation effects of therapeutic radiopharmaceutical agents. This is to help minimise the risk of late occurring radiation toxicities in clinical trials. Other guidance are available for conventional non-safety studies but this guidance focuses solely on late radiation safety concerns that are unique to therapeutic radiopharmaceuticals. The unique safety concerns result from the risk of irreversible toxicity when these agents deliver high dose of ionising radiation to normal organs.
full guidance given below
Posted in pre-clinical
Tagged FDA, late radiation, Nonclinical, safety evaluation, therapeutic radiopharmaceuticals
The FDA has brought together all the its bioequivalence recommendations for specific products into one online database, over the years a number of specific recommendations have been made across a large number of products. These recommendations are now brought together in a single database (currently containing 890 products) which can be accessed through the FDA website link provided below, this is specifically aimed at people developing “generic biological” products to give them an understanding of expectations of the FDA with regard to bioequivalence.
FDA thePage http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm#.TrufoqKWmLA.email
The guidance covers critical clinical considerations for investigational studies in phase 1 and two clinical trials and phase 3 clinical trials. The guidance makes recommendations for the design of clinical trials conducted under an IND to spot subsequent biological license applications. This is finalisation draft guidance was published in September 2009.
the product discussed in this guidance are therapeutic cancer vaccines intended to result in specific responses to tumour antigens and are intended to treat patients with an existing cancer. These products are traditionally regulated by the Centre for Biological Evaluation Research (CBER) and are referred to as cancer vaccines throughout this document.
Full Text Here
The European Medicines Agency (EMA) and the United States Food and Drug Administration
(FDA) have set up a new ‘cluster’ on biosimilar medicines.
Clusters are topic areas of mutual interest for the two agencies, which they have identified as benefiting from the regular exchange of information and collaborative meetings. Biosimilar medicines is the latest addition to the existing list of topics, which already includes medicines to treat cancer, orphan medicines, medicines for children and blood-based products.
The new cluster will allow the two agencies to increase their degree of interaction and will begin with a kick-off meeting to discuss the group’s activities. The group will follow this with discussions by teleconference around three times a year.
This is the latest step in the two agencies’ ongoing collaboration on regulatory issues under their confidentiality arrangements, which they first signed in 2003. The degree of interaction between the EMA and the FDA has increased significantly since then, to the current stable level of around 55 interactions per month, according to the first report on interactions between the two agencies, published today.
The report, which covers regular and ad-hoc interactions, emphasises the close level of collaboration between the two agencies, including the exchange of staff and regular staff visits, the co-ordination of communication on high-profile issues and the exchange of information on topics of shared interest.
The agencies plan to issue an report on their interactions every year.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
The aim of this workshop is to provide regulatory assistance to sponsors developing orphan drug designation applications.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
According to the FDA half for all medical devices used in USA are imported while 80% of active pharmaceutical ingredients sold in the US and manufactured elsewhere, and this trend is increasing.
The FDA has unveiled a new global strategy to help ensure the safety and quality of imported products and increasingly complex global supply chain..
” global production of FDA regulated goods exploded over the past 10 years. In addition to increasing import finished products, manufacturers increasingly use imported materials ingredients in a US production facilities, making the distinction between domestic and imported products obsolete” said Margaret Hamburg Commissioner of the FDA. A dramatic change in strategy must be implemented.
According to the report published by the FDA the FDA’s international operating model will rely on enhanced intelligence, information sharing, data driven risk analysis, and smart allocation of resources through partnerships.
the new approach will rest on four core building blocks:
This is another example of increasing globalisation pharmaceutical industry, regulators and no longer operating geographically distinct silos, by reaching out to each other to enforce strict adherence to ICH based regulatory perspectives. Other examples of this include joint EU FDA evaluation processes for orphan drugs, manufacturing quality, and quality by design. Where will this trend lead remains to be seen, but it is clear that everybody operating the pharmaceutical, biotechnology and medical devices industies needs to think globally.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
This guidance provides recommendations to applicants regarding requests for waivers, refunds, and reductions of user fees assessed under sections 735 and 736 of the Federal Food, Drug, and Cosmetic Act (the Act) for drugs, including biological drug products. This guidance is a revision of the draft guidance entitled Draft Interim Guidance Document for Waivers of and Reductions in User Fees (1993 interim guidance), issued July 16, 1993.
This revised guidance describes (1) the types of waivers, refunds, and reductions available under the user fee provisions of the Act and (2) the procedures for requesting waivers, refunds, or reductions, and reconsiderations and appeals of FDA decisions on such requests. The revised guidance also provides clarification on related issues such as user fee exemptions for orphan drugs.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
In addition to the oversight requirements afforded to the Food and Drug Administration (FDA) under Section 506B of the Federal Food, Drug and Cosmetic Act (FDCA),1 the Food and Drug Administration Amendments Act of 2007 (FDAAA) expanded authority to require sponsors of marketed drug and biologic products to conduct and report on their postmarketing studies and trials. A postmarketing requirement (PMR) is a study or trial that a sponsor is required by statute or regulation to conduct post-approval. A postmarketing commitment (PMC) is a study or trial that a sponsor agrees in writing to conduct after approval of the product. PMCs are typically designed to gather additional information about product safety, efficacy, or optimal use, and FDA has determined through a carefully deliberated process that the information is not a condition of approval.
Section 506B of the FDCA requires FDA to track and monitor the progress of PMRs and PMCs to ensure they are completed in a timely manner. FDA accomplishes this task primarily by reviewing the annual status reports submitted by the sponsor for completeness and accuracy. Section 921 of FDAAA added a requirement for FDA to review the entire Backlog of postmarketing requirements and commitments on an annual basis to determine which requirements/commitments should be revised or released. The objectives of this annual task were to:
• Propose recommendations for FDA re-evaluation or closure of PMRs and PMCs
• Identify PMRs and PMCs that need completion dates
• Analyze requirements/commitments that are recommended for closure/re-evaluation to determine why the studies or clinical trials may be no longer necessary or feasible
For the first annual Backlog review, completed and documented in a final report dated April 10, 2009, FDA queried internal PMR/PMC tracking systems on September 30, 2007 to produce a list of open non-Chemistry, Manufacturing, and Controls (CMC) PMRs and PMCs, which was modified based on identification of additional PMRs/PMCs. The review was based on a cohort of 1531 open PMRs/PMCs that were part of the PMR/PMC Backlog as of September 27, 2007. During the course of the second annual review, Booz Allen discovered additional PMRs/PMCs that were erroneously included in or excluded from this group. After accounting for these issues, the actual PMR/PMC Backlog as of September 27, 2007, consisted of 1551 open PMRs/PMCs. Current actual PMR/PMC status was determined based on data gathered from internal FDA systems and documents from the document room archives. Once the accurate statuses were determined, the Backlog PMRs/PMCs were prioritized for detailed review based on the prioritization scheme developed during the first annual review and used to develop recommendations. Recommendations will be validated by review division advisory groups and tracking coordinators, who will accept or revise the recommendations.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
In January the FDA released to the public and began implementing thei r2010 strategic plan. The plan, CDRH FY 2010 Strategic Priorities, identified four priority areas of activity that presented significant opportunities to improve our effectiveness in fulfilling our mission. In an effort to set both clear and aggressive timelines, the strategic plan included time‐bound goals associated with each strategy we were planning to implement, and time‐bound actions associated with the goals listed under each strategy.
We committed to achieve many of the goals in fiscal year (FY) 2010. For those goals that would take longer to accomplish, we identified the supporting actions we would take in FY 2010 to stay on track. In total, we committed to 123 actions, with 107 of those actions due in FY 2010. Recognizing that by setting aggressive timeliness many of the deadlines we set for ourselves were really stretch goals, we set as our performance target accomplishing at least 85 percent of the actions with due dates in the fiscal year.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of FDA’s Office of Orphan Products Development (OPD) grant program. The goal of FDA’s OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application’s Background and Significance section documentation to support the estimated prevalence of the orphan disease or condition (or in the case of a vaccine or diagnostic, information to support the estimates of how many people will be administered the diagnostic or vaccine annually) and an explanation of how the proposed study will either help support product approval or provide essential data needed
for product development.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Posted in Fund raising, regulatory
Tagged FDA, grant, OPD, Orphan Products Development
full text here
The European Medicines Agency (EMA) and the Food and Drug Administration of the United States of America (US FDA) continue to seek potential candidate companies for a joint GMP inspection pilot programme for manufacturers of medicinal products. Companies that have submitted in parallel two equivalent marketing authorisation applications for the same medicinal product to both the EMA and the US FDA can request to participate in the pilot programme for joint pre-approval inspection should such an inspection be considered necessary by both agencies.
The overall objective is to see whether greater international collaboration can help to distribute inspection capacity allowing more manufacturing sites to be monitored and reducing unnecessary duplication.
Companies can also participate in the pilot exercise by hosting a single join re-inspection (routine surveillance) where both the EMA and the US FDA have separately planned routine surveillance inspections (re-inspections) to take place within a similar time period at a manufacturing site of a medicinal product authorised in the USA and centrally authorised in the European Union.
Companies that wish to participate should contact either gmp@ema.europa.eu and/or CDERInternationalGMP@fda.hhs.gov.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
If you have questions about device development get in touch.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
This guidance provides information on the implementation of section 1102 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), which adds new section 524 to the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360n). Section 524 authorizes FDA to award priority review vouchers to sponsors of certain tropical disease product applications that meet the criteria specified by the Act. A priority review voucher may be used by the sponsor who obtains it or another sponsor to obtain a priority review for a different application. A priority review voucher may be transferred from the sponsor who obtains it to another sponsor.
These vouchers are valued at between US$50 and US$300 million, and there is grant money available to fund development it is a great way of generating large anounts of value whilst saving lives.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
This guidance is intended to help the public, Food and Drug Administration (FDA) advisory committee members, and FDA staff to understand and implement statutory requirements and FDA policy regarding public availability of information about financial interests and waivers granted by FDA to permit individuals to participate in advisory committee meetings subject to the Federal Advisory Committee Act (FACA) (5 U.S.C. App. 2). This guidance describes the basis and provides a format for public disclosure of certain financial interests by special Government employees (SGEs) and regular Government employees participating in these advisory committee meetings, and provides a format for FDA waivers allowing participation in these meetings. This guidance also explains how and when these documents will be made publicly available by FDA.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Full Text Here
The purpose of this document is to recommend international standards for, and promote harmonization of, the nonclinical safety studies recommended to support human clinical trials of a given scope and duration as well as marketing authorization for pharmaceuticals. Harmonization of the guidance for nonclinical safety studies will help to define the current recommendations and reduce the likelihood that substantial differences will exist among regions.
This is a revision of the ICH guidance “M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals” that published in 1997. The revisions further harmonize recommendations in a number of areas and include a new section on exploratory clinical studies. This revised guidance discusses other nonclinical studies that should be conducted on a case-by-case basis as appropriate, including phototoxicity studies, immunotoxicity studies, juvenile animal toxicity studies, and abuse potential studies.
This guidance should facilitate the timely conduct of clinical trials, reduce the use of animals in accordance with the 3R (reduce/refine/replace) principles, and reduce the use of other drug development resources. Although not discussed in this guidance, consideration should be given to use of new in vitro alternative methods for safety evaluation. These methods, if validated and accepted by all ICH regulatory authorities, can be used to replace current standard methods. This guidance promotes safe, ethical development and availability of new pharmaceuticals.
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.
Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free
“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”
Posted in pre-clinical
Tagged FDA, ICH, ICH M3(R2), ICHM3, ICHM3(R2), Non-clinical, preclinical, requirements
FulL Text Here
This guidance provides recommendations to pharmacies on the advance compounding of Tamilfu oral suspension to provide multiple prescriptions. FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
BBC Health News